Display options
Cite
Akbarin MM, Rahimi H, Hassannia T, et al. Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers. Iran J Basic Med Sci. 2013;16(3):208-12
Akbarin, M. M., Rahimi, H., Hassannia, T., Shoja Razavi, G., Sabet, F., & Shirdel, A. (2013). Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers. Iranian journal of basic medical sciences, 16(3), 208-12.
Akbarin, Mohammad Mehdi, et al. "Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers." Iranian journal of basic medical sciences vol. 16,3 (2013): 208-12.
Akbarin MM, Rahimi H, Hassannia T, Shoja Razavi G, Sabet F, Shirdel A. Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers. Iran J Basic Med Sci. 2013 Mar;16(3):208-12. PMID: 24470863; PMCID: PMC3881246.
Copy Download .nbib Format: NLM
Share it on

Iran J Basic Med Sci. 2013 Mar;16(3):208-12.

Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers.

Iranian journal of basic medical sciences

Mohammad Mehdi Akbarin, Hossein Rahimi, Tahereh Hassannia, Ghazaleh Shoja Razavi, Faezeh Sabet, Abbas Shirdel

Affiliations

  1. Inflammation and inflammatory research centre, Medical School, Mashhad University of Medical Science, Mashhad- Iran.
  2. Inflammation and inflammatory research centre, Medical School, Mashhad University of Medical Science, Mashhad- Iran ; Internal medicine Dept. Medical School, Mashhad University of Medical Science, Mashhad- Iran.
  3. Internal Medicine Dept, Amir al Moemenin Hospital, Arak University of Medical Sciences.
  4. Internal medicine Dept. Medical School, Mashhad University of Medical Science, Mashhad- Iran.
  5. Navid Medical Lab, Mashhad- Iran.

PMID: 24470863 PMCID: PMC3881246

Abstract

OBJECTIVE(S): Human T Lymphocyte Virus Type one (HTLV-I) is a retrovirus that infects about 10-20 million people worldwide. Khorasan province in Iran is an endemic area. The majority of HTLV-I-infected individuals sustain healthy carriers but small proportion of infected population developed two progressive diseases: HAM/TSP and ATL. The proviral load could be a virological marker for disease monitoring, therefore in the present study HTLV-I proviral load has been evaluated in ATL and compared to HAM/TSP and healthy carriers.

MATERIALS AND METHODS: In this case series study, 47 HTLV-I infected individuals including 13 ATL, 23 HAM/TSP and 11 asymptomatic subjects were studied. Peripheral blood mononuclear cells (PBMCs) were investigated for presence of HTLV-I DNA provirus by PCR using LTR and Tax fragments. Then in infected subjects, HTLV-I proviral load was measured using real time PCR TaqMan method.

RESULTS: The average age of patients in ATL was 52±8, in HAM/TSP 45.52±15.17 and in carrier's 38.65±14.9 years which differences were not statistically significant. The analysis of data showed a significant difference in mean WBC among study groups (ATL vs HAM/TSP and carriers P=0.0001). Moreover, mean HTLV-I proviral load was 11967.2 ± 5078, 409 ± 71.3 and 373.6 ± 143.3 in ATL, HAM/TSP and Healthy Carriers, respectively. The highest HTLV-I proviral load was measured in ATL group that had a significant correlation with WBC count (R=0.495, P=0.001). The proviral load variations between study groups was strongly significant (ATL vs carrier P=0.0001; ATL vs HAM/TSP P= 0.0001 and HAM/TSP vs carriers P< 0.05). Conclusion : The present study demonstrated that HTLV-I proviral load was higher in ATL group in comparison with HAM/TSP and healthy carriers. Therefore, HTLV-I proviral load is a prognostic factor for development of HTLV-I associated diseases and can be used as a monitoring marker for the efficiency of therapeutic regime.

Keywords: ATL; HAM/TSP; HTLV-I; HTLV-I proviral load

References

  1. AIDS Res Hum Retroviruses. 2012 Sep;28(9):1095-1101 - PubMed
  2. J Clin Exp Hematop. 2010;50(1):9-25 - PubMed
  3. J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):92-100 - PubMed
  4. J Neuroimmunol. 2012 Sep 15;250(1-2):87-93 - PubMed
  5. Virus Res. 2008 Jul;135(1):22-5 - PubMed
  6. Oncogene. 2005 Sep 5;24(39):5926-30 - PubMed
  7. Case Rep Neurol Med. 2012;2012:958786 - PubMed
  8. Front Microbiol. 2012 Nov 30;3:406 - PubMed
  9. Virus Res. 2012 Jan;163(1):87-90 - PubMed
  10. Virol J. 2012 Mar 23;9:71 - PubMed
  11. J Clin Virol. 2012 Apr;53(4):302-7 - PubMed
  12. Viruses. 2011 Jun;3(6):750-69 - PubMed
  13. J Infect Dis. 2011 Apr 1;203(7):948-59 - PubMed
  14. Leuk Lymphoma. 2004 Apr;45(4):715-21 - PubMed
  15. PLoS Negl Trop Dis. 2013;7(2):e2028 - PubMed
  16. Blood. 2009 Jun 25;113(26):6528-32 - PubMed
  17. Interdiscip Perspect Infect Dis. 2010;2010:478461 - PubMed
  18. Br J Haematol. 1999 May;105(2):369-75 - PubMed
  19. J Neurovirol. 2006 Dec;12(6):456-65 - PubMed
  20. Transfus Apher Sci. 2012 Oct;47(2):151-4 - PubMed
  21. Leuk Res. 2012 Jul;36(7):857-61 - PubMed
  22. Leukemia. 1994 Oct;8(10):1763-7 - PubMed
  23. Front Microbiol. 2012 Nov 09;3:389 - PubMed
  24. J Clin Virol. 2011 Nov;52(3):172-6 - PubMed
  25. Acad Radiol. 2012 Aug;19(8):952-7 - PubMed
  26. J Neurovirol. 1998 Dec;4(6):586-93 - PubMed
  27. Blood. 2010 Aug 26;116(8):1211-9 - PubMed

Publication Types